Drug Development

Share SHARE

pills-112014.jpg Purdue Pharma LP has won approval from the FDA for its extended release, abuse deterrent hydrocodone painkiller, Hysingla ER. The pill is designed to be difficult to be crushed for snorting and prepared for injection. "While the science of abuse deterrence is still evolving, the development of opioids that are harder to abuse is helpful in addressing the public health crisis . . ."

drugbust-pills-111814.jpg Over the past decade, the cost of developing a new drug has tripled, now requiring $2.56 billion, according to research conducted at the Tufts Center for the Study of Drug Development. The study based its results on data on the reports of ten drug companies and 106 experimental products. "This is a very high number," Kenneth I. Kaitin, director of the Tufts center, told the Boston Globe.

hypodermicneedle-052812_10Jul12.jpg The FDA has approved Trumenba, a vaccine that may help prevent the invasive meningococcal disease caused by Neisseria meningitidis serogroup B bacteria. The bacteria is the leading cause of meningitis and is spread through the exchange of oral fluids. "Recent outbreaks of serogroup B meningococcal disease on a few college campuses have heightened concerns for this potentially deadly disease."

hypodermicneedle-052812_10Jul12.jpg A new vaccine for meningitis has been greenlighted by the U.S. Food and Drug Administration. The vaccine, Trumenba, is approved for protection in people 10-25 years of age against meningococcal disease caused by Neisseria meningitidis serogroup B bacteria, of which there were outbreaks last year at Princeton University and the University of California Santa Barbara.

Painrelief-102414.jpg Contract Packaging Resources is recalling nearly 12,000 boxes of the Assured brand naproxen pain relief tablets shipped to Dollar Tree outlets. The recall was issued for 15 count bottles of 220 mg tablets of naproxen sodium, which may actually contain bottles of ibuprofen softgels in 200 mg strength. The ibuprofen tablets represent a threat to those with allergies to the drug.

vancomycin-102014.jpg Vancomycin, an older antibiotic, is still effective in treating Staphylococcus aureus (staph disease) blood infections, according to research conducted at the University of Nebraska. The study, published in the Journal of the American Medical Association, surveyed data on nearly 8,300 cases of staph.